Case number 2016-2206
Genzyme Corporation v. Dr. Reddy's Laboratories, Ltd > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | GENZYME CORPORATION v. DR. REDDY'S LABORATORIES, LTD [OPINION] [nonprecedential] (0) |
| Jan 24, 2018 | 67 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by Clerk of Court. [492290] [16-2206, 16-2207] [SJ] [Entered: 01/24/2018 11:44 AM] (1) |
| Dec 18, 2017 | 66 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (Nonprecedential Opinion). (For the Court: Moore,Circuit Judge; Plager,Circuit Judge and Chen,Circuit Judge). [483209] [16-2206, 16-2207] [JAB] [Entered: 12/18/2017 09:58 AM] (13) |
| Oct 4, 2017 | 65 | Submitted after ORAL ARGUMENT by Martin B. Pavane for Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. and Paul Henry Berghoff for Genzyme Corporation and Sanofi-Aventis U.S., LLC. Panel: Judge: Moore , Judge: Plager , Judge: Chen. [465527] [JAB] [Entered: 10/04/2017 01:53 PM] (0) |
| Sep 29, 2017 | 64 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. Service: 09/29/2017 by email. [464395] [Martin Pavane] [Entered: 09/29/2017 02:22 PM] (1) |
| Sep 6, 2017 | 63 | Response to oral argument order from the Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. designating Paul H. Berghoff as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [458880] [Paula Fritsch] [Entered: 09/06/2017 11:52 AM] (0) |
| Sep 1, 2017 | 62 | Response to oral argument order from the Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. designating Martin B. Pavane as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [458182] [Martin Pavane] [Entered: 09/01/2017 09:33 AM] (0) |
| Aug 21, 2017 | 61 | NOTICE OF CALENDARING. Panel: 1710K. Case scheduled Oct 04, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 201. Response to oral argument order due: 09/15/2017. Arguing counsel is required to check-in at the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [455381] [JAB] [Entered: 08/21/2017 01:12 PM] (0) |
| Mar 20, 2017 | 60 | Notice from Appellants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. regarding conflicts with oral argument (April 3-10, 2017; May 2-5, 2017; June 6-7, 2017; August 7-11, 2017; September 5-8, 2017). Service: 03/20/2017 by email. [417171] [Martin Pavane] [Entered: 03/20/2017 06:25 PM] (1) |
| Mar 20, 2017 | 59 | Notice from Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC regarding conflicts with oral argument (Conflicts week of June 5-9, 2017). Service: 03/20/2017 by email. [417061] [Paula Fritsch] [Entered: 03/20/2017 03:24 PM] (1) |
| Mar 16, 2017 | 58 | 6 paper copies of the Joint Appendix (Vol. I-II) [56] received from Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Teva Pharmaceuticals USA Inc and Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. [416286] [KW] [Entered: 03/16/2017 02:57 PM] (0) |
| Mar 14, 2017 | 57 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 03/21/2017. [415522] [JB] [Entered: 03/14/2017 05:00 PM] (0) |
| Mar 14, 2017 | 55 | Statement of Compliance with Fed. Cir. R. 33 for Appellant Teva Pharmaceuticals USA Inc. Service: 03/14/2017 by email. [415353] [Elaine Blais] [Entered: 03/14/2017 02:30 PM] (3) |
| Mar 14, 2017 | 54 | 6 paper copies of the Corrected Reply Brief [51] received from Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. [415328] [KW] [Entered: 03/14/2017 02:06 PM] (0) |
| Mar 13, 2017 | 56 | APPENDIX FILED for Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Teva Pharmaceuticals USA Inc and Genzyme Corporation and Sanofi-Aventis U.S., LLC [52]. Number of Pages: 926. Service: 03/13/2017 by email. The paper copies of the brief should be received by the court on or before 03/21/2017. [415521] [JB] [Entered: 03/14/2017 04:59 PM] (926) |
| Mar 13, 2017 | 53 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 03/13/2017 by email. [415106] [Martin Pavane] [Entered: 03/13/2017 08:46 PM] (5) |
| Mar 13, 2017 | 52 | TENDERED from Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Teva Pharmaceuticals USA Inc and Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Title: JOINT APPENDIX. Service: 03/13/2017 by email. [415097] [Martin Pavane] [Entered: 03/13/2017 06:52 PM] (926) |
| Mar 10, 2017 | 51 | CORRECTED REPLY BRIEF FILED for Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc [50]. Number of Pages: 29. Service: 03/10/2017 by email. The paper copies of the brief should be received by the court on or before 03/17/2017. [414461] [JB] [Entered: 03/10/2017 02:19 PM] (42) |
| Mar 10, 2017 | 50 | TENDERED from Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. Title: CORRECTED REPLY BRIEF. Service: 03/10/2017 by email. [414403] [Martin Pavane] [Entered: 03/10/2017 01:23 PM] (42) |
| Mar 10, 2017 | 49 | Notice of Correction to the Brief Doc No. [46] for Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. Service: 03/10/2017 by email. [414401] [Martin Pavane] [Entered: 03/10/2017 01:22 PM] (9) |
| Mar 9, 2017 | 48 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Brief Docket No. [46], ERROR: Some of the appendix references in the brief [390276-2] did not follow the format specified in FCR 30(b)(4)(E) as required by FCR 28(f). As an example, "Appx12008, 12013-12015" on pg. 14 and Appx3128-3130, 3148-3149 on pg. 25 are non-compliant.. CORRECTION: When referring to multiple pages or page ranges of an appendix, each individual page or range must be preceded by "Appx." For the example, the correct reference would be "Appx12008, Appx12013-12015 and Appx3128-3130, Appx3148-3149." For future briefs, please ensure all references are compliant.. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [413686] [JB] [Entered: 03/09/2017 08:22 AM] (0) |
| Mar 7, 2017 | 47 | REPLY BRIEF FILED for Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc [46]. Number of Pages: 29. Service: 03/07/2017 by email. The paper copies of the brief should be received by the court on or before 03/16/2017. Appendix is due 03/14/2017. [413682] This brief has been corrected. See Doc No [51] [JB] [Entered: 03/09/2017 08:11 AM] (0) |
| Mar 7, 2017 | 46 | TENDERED from Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. Title: REPLY BRIEF. Service: 03/07/2017 by email. [413204] This brief has been corrected. See Doc No [51] [Martin Pavane] [Entered: 03/07/2017 08:08 PM] (0) |
| Feb 17, 2017 | 45 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [44] filed by Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. Reply brief is due on 03/07/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [408599] [JB] [Entered: 02/17/2017 11:57 AM] (0) |
| Feb 16, 2017 | 44 | MOTION of Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc to extend the time to 03/07/2017 at 11:59 pm to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 02/16/2017 by email. [408435] [Martin Pavane] [Entered: 02/16/2017 06:45 PM] (10) |
| Jan 31, 2017 | 43 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [42] filed by Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. Reply brief is due 02/21/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [403283] [JB] [Entered: 01/31/2017 09:42 AM] (0) |
| Jan 30, 2017 | 42 | MOTION of Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc to extend the time to 02/21/2017 to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/30/2017 by email. [403212] [Martin Pavane] [Entered: 01/30/2017 05:51 PM] (8) |
| Jan 30, 2017 | 41 | 6 paper copies of the Response Brief [40] received from Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. [403082] [KW] [Entered: 01/30/2017 01:58 PM] (0) |
| Jan 23, 2017 | 40 | BRIEF FILED for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC [39]. Number of Pages: 66. Service: 01/23/2017 by email. The paper copies of the brief should be received by the court on or before 01/31/2017. Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc reply brief is due 02/06/2017. [401444] [JB] [Entered: 01/24/2017 02:55 PM] (85) |
| Jan 23, 2017 | 39 | TENDERED from Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Title: RESPONSE BRIEF. Service: 01/23/2017 by email. [401057] [Paula Fritsch] [Entered: 01/23/2017 11:49 PM] (85) |
| Jan 19, 2017 | 38 | Letter from Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC Brief due date due to holiday. Service: 01/19/2017 by email. [400529] [Paula Fritsch] [Entered: 01/19/2017 05:37 PM] (1) |
| Oct 25, 2016 | 37 | **TEXT ONLY** ORDER granting motion to extend time to file appellee/respondent/cross-appellant principal brief [36] filed by Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC brief due 01/20/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [377318] [JB] [Entered: 10/25/2016 09:28 AM] (0) |
| Oct 24, 2016 | 36 | MOTION of Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC to extend the time to 01/20/2017 to file the appellee/respondent/cross-appellant's principal brief. Response/Opposition is due 11/03/2016 [Consent: unopposed]. Service: 10/24/2016 by email. [377224] [Paula Fritsch] [Entered: 10/24/2016 04:22 PM] (8) |
| Oct 14, 2016 | 35 | 6 paper copies of the Opening Brief [34] received from Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. [374424] [KW] [Entered: 10/14/2016 03:14 PM] (0) |
| Oct 11, 2016 | 34 | BRIEF FILED for Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc [33]. Number of Pages: 61. Service: 10/11/2016 by email. The paper copies of the brief should be received by the court on or before 10/18/2016. Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC brief is due 11/21/2016. [373853] [JB] [Entered: 10/13/2016 12:29 PM] (130) |
| Oct 11, 2016 | 33 | TENDERED from Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. Title: OPENING BRIEF. Service: 10/11/2016 by email. [373318] [Martin Pavane] [Entered: 10/11/2016 08:17 PM] (130) |
| Jul 26, 2016 | 32 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [353631] [JB] [Entered: 07/26/2016 11:45 AM] (0) |
| Jul 21, 2016 | 31 | **TEXT ONLY** ORDER granting motion to extend time to file appellants' principal brief [30] filed by Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc. Brief due 10/11/2016. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [352538] [MJL] [Entered: 07/21/2016 10:53 AM] (0) |
| Jul 20, 2016 | 30 | MOTION of Appellants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. and Teva Pharmaceuticals USA Inc to extend the time to 10/11/2016 to file the appellant/petitioner's principal brief. Response/Opposition is due 08/04/2016 [Consent: unopposed]. Service: 07/20/2016 by email. [352436] [William Jay] [Entered: 07/20/2016 05:06 PM] (12) |
| Jul 11, 2016 | 29 | Clerk's Note to the File: Paper documents filed with the court are not accepted. All filings made by counsel should be submitted electronically on CM/ECF. [349839] [JB] [Entered: 07/11/2016 02:54 PM] (0) |
| Jun 28, 2016 | 28 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The entries of appearance for Elaine H. Blais [20] and Emily L. Rapalino [24] contain contact information that does not match the contact information in the attorneys' user accounts. CORRECTION: Please update as needed to ensure the contact information on the entries of appearance and in the user accounts matches. [346929] [MJL] [Entered: 06/28/2016 10:28 AM] (0) |
| Jun 27, 2016 | 27 | Docketing Statement for the Appellant Teva Pharmaceuticals USA Inc. Service: 06/27/2016 by email. [346854] [Elaine Blais] [Entered: 06/27/2016 09:27 PM] (3) |
| Jun 27, 2016 | 26 | Certificate of Interest for the Appellant Teva Pharmaceuticals USA Inc. Service: 06/27/2016 by email. [346853] [Elaine Blais] [Entered: 06/27/2016 09:25 PM] (2) |
| Jun 27, 2016 | 25 | Entry of appearance for Alexandra D. Valenti as of counsel for Appellant Teva Pharmaceuticals USA Inc. Service: 06/27/2016 by email. [346851] [Alexandra Valenti] [Entered: 06/27/2016 09:20 PM] (2) |
| Jun 27, 2016 | 24 | Entry of appearance for Emily L. Rapalino as of counsel for Appellant Teva Pharmaceuticals USA Inc. Service: 06/27/2016 by email. [346849] [Emily Rapalino] [Entered: 06/27/2016 09:16 PM] (2) |
| Jun 27, 2016 | 23 | Entry of appearance for William M. Jay as of counsel for Appellant Teva Pharmaceuticals USA Inc. Service: 06/27/2016 by email. [346848] [William Jay] [Entered: 06/27/2016 09:13 PM] (2) |
| Jun 27, 2016 | 22 | Entry of appearance for Natasha E. Daughtrey as of counsel for Appellant Teva Pharmaceuticals USA Inc. Service: 06/27/2016 by email. [346847] [Natasha Daughtrey] [Entered: 06/27/2016 09:10 PM] (2) |
| Jun 27, 2016 | 21 | Entry of appearance for Michael B. Cottler as of counsel for Appellant Teva Pharmaceuticals USA Inc. Service: 06/27/2016 by email. [346846] [Michael Cottler] [Entered: 06/27/2016 09:07 PM] (2) |
| Jun 27, 2016 | 20 | Entry of appearance for Elaine H. Blais as principal counsel for Appellant Teva Pharmaceuticals USA Inc. Service: 06/27/2016 by email. [346845] [Elaine Blais] [Entered: 06/27/2016 09:02 PM] (2) |
| Jun 23, 2016 | 19 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: When submitting documents [9], [10], [11], [12], [13], [14], [15], and [16], filer selected "clerk" as a method of service. CORRECTION: When serving a document through the court's CM/ECF system, "email" is the appropriate method of service. For future filings, please ensure the appropriate method of service is selected. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [345913] [MJL] [Entered: 06/23/2016 08:39 AM] (0) |
| Jun 23, 2016 | 18 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Paul H. Berghoff, Alison J. Baldwin, and Jeremy E. Noe (entries of appearance [9], [11], and [13]) are not registered CM/ECF filers for the Federal Circuit. CORRECTION: Pursuant to FCR 25(a)(2), attorneys who appear before this court must register for the court's CM/ECF system. Please register promptly. [345911] [MJL] [Entered: 06/23/2016 08:31 AM] (0) |
| Jun 22, 2016 | 17 | Certificate of Interest for the Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email. [345885] [Paula Fritsch] [Entered: 06/22/2016 04:52 PM] (2) |
| Jun 22, 2016 | 16 | Docketing Statement for the Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email, clerk. [345884] [Paula Fritsch] [Entered: 06/22/2016 04:51 PM] (3) |
| Jun 22, 2016 | 15 | Entry of appearance for Kurt William Rohde as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email, clerk. [345883] [Paula Fritsch] [Entered: 06/22/2016 04:50 PM] (2) |
| Jun 22, 2016 | 14 | Entry of appearance for Jeffrey B. Bove as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email, clerk. [345882] [Paula Fritsch] [Entered: 06/22/2016 04:49 PM] (2) |
| Jun 22, 2016 | 13 | Entry of appearance for Jeremy E. Noe as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email, clerk. [345881] [Paula Fritsch] [Entered: 06/22/2016 04:48 PM] (2) |
| Jun 22, 2016 | 12 | Entry of appearance for James L. Lovsin as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email, clerk. [345880] [Paula Fritsch] [Entered: 06/22/2016 04:47 PM] (2) |
| Jun 22, 2016 | 11 | Entry of appearance for Alison J. Baldwin as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email, clerk. [345879] [Paula Fritsch] [Entered: 06/22/2016 04:46 PM] (2) |
| Jun 22, 2016 | 10 | Entry of appearance for Paula S. Fritsch as of counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email, clerk. [345878] [Paula Fritsch] [Entered: 06/22/2016 04:45 PM] (2) |
| Jun 22, 2016 | 9 | Entry of appearance for Paul H. Berghoff as principal counsel for Appellees Genzyme Corporation and Sanofi-Aventis U.S., LLC. Service: 06/22/2016 by email, clerk. [345877] [Paula Fritsch] [Entered: 06/22/2016 04:43 PM] (2) |
| Jun 20, 2016 | 8 | Transcript Purchase Order Form for the Appellants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. indicating that a transcript is already on file. Service: 06/20/2016 by email. [344934] [Martin Pavane] [Entered: 06/20/2016 12:34 PM] (2) |
| Jun 16, 2016 | 7 | Docketing Statement for the Appellants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 06/16/2016 by email. [344142] [Martin Pavane] [Entered: 06/16/2016 12:03 PM] (4) |
| Jun 16, 2016 | 6 | Amended Certificate of Interest for the Appellants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 06/16/2016 by email. [344108] [Martin Pavane] [Entered: 06/16/2016 11:02 AM] (2) |
| Jun 15, 2016 | 5 | Entry of appearance for Marilyn Neiman as of counsel for Appellants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 06/15/2016 by email. [343902] [Marilyn Neiman] [Entered: 06/15/2016 03:50 PM] (2) |
| Jun 15, 2016 | 4 | Certificate of Interest for the Appellants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 06/15/2016 by email. [343900] [Martin Pavane] [Entered: 06/15/2016 03:47 PM] (2) |
| Jun 15, 2016 | 3 | Entry of appearance for Martin B. Pavane as principal counsel for Appellants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.. Service: 06/15/2016 by email. [343899] [Martin Pavane] [Entered: 06/15/2016 03:46 PM] (2) |
| Jun 13, 2016 | 2 | Note to file: The following cases are associated:16-2206 Lead with 16-2207 Consolidated.. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [342847] [JB] [Entered: 06/13/2016 10:27 AM] (0) |
| Jun 13, 2016 | 1 | Appeal docketed. Received: 06/10/2016. [342808]Entry of Appearance due 06/27/2016. Certificate of Interest is due on 06/27/2016. Docketing Statement due 06/27/2016. Appellant/Petitioner's brief is due 08/12/2016. [JB] [Entered: 06/13/2016 09:36 AM] (35) |
